{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:55:28Z","timestamp":1791338128222,"version":"4.3.1"},"reference-count":230,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.gendis.2023.06.037","type":"journal-article","created":{"date-parts":[[2023,8,6]],"date-time":"2023-08-06T05:19:44Z","timestamp":1691299184000},"page":"101070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["The role of proteasomes in tumorigenesis"],"prefix":"10.1016","volume":"11","author":[{"given":"Xiangyi","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4589-0599","authenticated-orcid":false,"given":"Tingxiu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.gendis.2023.06.037_bib1","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/80992","article-title":"A gated channel into the proteasome core particle","volume":"7","author":"Groll","year":"2000","journal-title":"Nat Struct Biol"},{"issue":"6624","key":"10.1016\/j.gendis.2023.06.037_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/386463a0","article-title":"Structure of 20S proteasome from yeast at 2.4 A resolution","volume":"386","author":"Groll","year":"1997","journal-title":"Nature"},{"issue":"40","key":"10.1016\/j.gendis.2023.06.037_bib3","doi-asserted-by":"crossref","first-page":"25200","DOI":"10.1074\/jbc.272.40.25200","article-title":"The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing","volume":"272","author":"Heinemeyer","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gendis.2023.06.037_bib4","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S0092-8674(03)00971-1","article-title":"Ubiquitin as a central cellular regulator","volume":"116","author":"Finley","year":"2004","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/sj.cdd.4401740","article-title":"Discovery of the ubiquitin proteasome system and its involvement in apoptosis","volume":"12","author":"Melino","year":"2005","journal-title":"Cell Death Differ"},{"issue":"32","key":"10.1016\/j.gendis.2023.06.037_bib6","doi-asserted-by":"crossref","first-page":"22123","DOI":"10.1074\/jbc.274.32.22123","article-title":"The proteasome, a novel protease regulated by multiple mechanisms","volume":"274","author":"DeMartino","year":"1999","journal-title":"J Biol Chem"},{"issue":"6968","key":"10.1016\/j.gendis.2023.06.037_bib7","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nature02263","article-title":"Protein degradation and protection against misfolded or damaged proteins","volume":"426","author":"Goldberg","year":"2003","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib8","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1053\/j.gastro.2014.07.001","article-title":"Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice","volume":"147","author":"Wang","year":"2014","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.gendis.2019.06.001","article-title":"A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance","volume":"6","author":"Wang","year":"2019","journal-title":"Genes Dis"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib10","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.cell.2012.05.012","article-title":"Wnt\/\u03b2-catenin signaling and disease","volume":"149","author":"Clevers","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5829","key":"10.1016\/j.gendis.2023.06.037_bib12","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.1141915","article-title":"Regulation of CD8\u207a T cell development by Thymus-specific proteasomes","volume":"316","author":"Shigeo","year":"2007","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coi.2012.11.004","article-title":"The immunoproteasome in antigen processing and other immunological functions","volume":"25","author":"Basler","year":"2013","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.gendis.2023.06.037_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/B978-0-12-397863-9.00008-0","article-title":"Proteasome and cancer","volume":"109","author":"Catalgol","year":"2012","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"11","key":"10.1016\/j.gendis.2023.06.037_bib15","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","article-title":"Ubiquitin-proteasome system (UPS) as a target for anticancer treatment","volume":"43","author":"Park","year":"2020","journal-title":"Arch Pharm Res (Seoul)"},{"issue":"11","key":"10.1016\/j.gendis.2023.06.037_bib16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41580-018-0040-z","article-title":"Regulation of proteasome assembly and activity in health and disease","volume":"19","author":"Rousseau","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"45","key":"10.1016\/j.gendis.2023.06.037_bib17","first-page":"3755","article-title":"New form of insulin: crystallized protamine insulin (NPH 50)","volume":"73","author":"Rudolf","year":"1951","journal-title":"Concours Med"},{"issue":"4390","key":"10.1016\/j.gendis.2023.06.037_bib18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/1721143a0","article-title":"Enzymic content of the mitochondria fraction","volume":"172","author":"DeDuve","year":"1953","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib19","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1042\/bj0600604","article-title":"Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue","volume":"60","author":"Duve","year":"1955","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0021-9258(18)71356-2","article-title":"The release of labeled amino acids from the proteins of rat liver slices","volume":"201","author":"Simpson","year":"1953","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0092-8674(81)90233-6","article-title":"The selective degradation of injected proteins occurs principally in the cytosol rather than in lysosomes","volume":"25","author":"Bigelow","year":"1981","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.gendis.2023.06.037_bib22","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.1980.tb07873.x","article-title":"Cation-sensitive neutral endopeptidase: isolation and specificity of the bovine pituitary enzyme","volume":"35","author":"Wilk","year":"1980","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib23","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1471-4159.1983.tb08056.x","article-title":"Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex","volume":"40","author":"Wilk","year":"1983","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0014-5793(85)80854-1","article-title":"Isolation of two forms of the high-molecular-mass serine protease, ingensin, from porcine skeletal muscle","volume":"189","author":"Ishiura","year":"1985","journal-title":"FEBS Lett"},{"issue":"22","key":"10.1016\/j.gendis.2023.06.037_bib25","doi-asserted-by":"crossref","first-page":"7545","DOI":"10.1073\/pnas.82.22.7545","article-title":"Purification of neutral lens endopeptidase: close similarity to a neutral proteinase in pituitary","volume":"82","author":"Ray","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0003-9861(88)90189-0","article-title":"ATP-stimulated proteolysis in soluble extracts of BHK 21\/C13 cells. Evidence for multiple pathways and a role for an enzyme related to the high-molecular-weight protease, macropain","volume":"262","author":"McGuire","year":"1988","journal-title":"Arch Biochem Biophys"},{"issue":"32","key":"10.1016\/j.gendis.2023.06.037_bib27","doi-asserted-by":"crossref","first-page":"15197","DOI":"10.1016\/S0021-9258(18)66853-X","article-title":"A high molecular weight protease in the cytosol of rat liver. I. Purification, enzymological properties, and tissue distribution","volume":"261","author":"Tanaka","year":"1986","journal-title":"J Biol Chem"},{"issue":"6152","key":"10.1016\/j.gendis.2023.06.037_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/331190a0","article-title":"Drosophila small cytoplasmic 19S ribonucleoprotein is homologous to the rat multicatalytic proteinase","volume":"331","author":"Falkenburg","year":"1988","journal-title":"Nature"},{"issue":"6152","key":"10.1016\/j.gendis.2023.06.037_bib29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/331192a0","article-title":"Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome)","volume":"331","author":"Arrigo","year":"1988","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.gendis.2023.06.037_bib30","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1073\/pnas.86.8.2597","article-title":"Involvement of the proteasome in various degradative processes in mammalian cells","volume":"86","author":"Matthews","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"10.1016\/j.gendis.2023.06.037_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-5793(88)81069-X","article-title":"Electron microscopy and image analysis of the multicatalytic proteinase","volume":"241","author":"Baumeister","year":"1988","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib32","first-page":"143","article-title":"The 22 S cylinder particles of Xenopus laevis. I. Biochemical and electron microscopic characterization","volume":"32","author":"Kleinschmidt","year":"1983","journal-title":"Eur J Cell Biol"},{"issue":"5210","key":"10.1016\/j.gendis.2023.06.037_bib33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1126\/science.7725097","article-title":"Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution","volume":"268","author":"L\u00f6we","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.gendis.2023.06.037_bib34","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1146\/annurev.bi.65.070196.004101","article-title":"Structure and functions of the 20S and 26S proteasomes","volume":"65","author":"Coux","year":"1996","journal-title":"Annu Rev Biochem"},{"issue":"40","key":"10.1016\/j.gendis.2023.06.037_bib35","doi-asserted-by":"crossref","first-page":"25637","DOI":"10.1074\/jbc.273.40.25637","article-title":"Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants","volume":"273","author":"Dick","year":"1998","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)80341-X","article-title":"Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown","volume":"4","author":"Kisselev","year":"1999","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.molcel.2017.06.007","article-title":"Conformational landscape of the p28-bound human proteasome regulatory particle","volume":"67","author":"Lu","year":"2017","journal-title":"Mol Cell"},{"issue":"7737","key":"10.1016\/j.gendis.2023.06.037_bib38","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41586-018-0736-4","article-title":"Cryo-EM structures and dynamics of substrate-engaged human 26S proteasome","volume":"565","author":"Dong","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.gendis.2023.06.037_bib39","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib40","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2010.07.036","article-title":"Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress","volume":"142","author":"Seifert","year":"2010","journal-title":"Cell"},{"issue":"Pt 1","key":"10.1016\/j.gendis.2023.06.037_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj3450001","article-title":"The proteasome activator 11 S REG (PA28) and class I antigen presentation","volume":"345","author":"Rechsteiner","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.gendis.2023.06.037_bib42","first-page":"73","article-title":"The 11S regulators of 20S proteasome activity","volume":"268","author":"Hill","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"issue":"11","key":"10.1016\/j.gendis.2023.06.037_bib43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nsb1194-765","article-title":"Critical elements in proteasome assembly","volume":"1","author":"Zwickl","year":"1994","journal-title":"Nat Struct Biol"},{"issue":"5211","key":"10.1016\/j.gendis.2023.06.037_bib44","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.7732382","article-title":"Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin","volume":"268","author":"Fenteany","year":"1995","journal-title":"Science"},{"issue":"1\u20133","key":"10.1016\/j.gendis.2023.06.037_bib45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0014-5793(93)81793-Y","article-title":"Thermoplasma acidophilum proteasomes degrade partially unfolded and ubiquitin-associated proteins","volume":"326","author":"Wenzel","year":"1993","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"issue":"4536","key":"10.1016\/j.gendis.2023.06.037_bib47","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1126\/science.7038874","article-title":"Oxidized proteins in erythrocytes are rapidly degraded by the adenosine triphosphate-dependent proteolytic system","volume":"215","author":"Goldberg","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.gendis.2023.06.037_bib48","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1146\/annurev.biochem.68.1.1015","article-title":"The 26S proteasome: a molecular machine designed for controlled proteolysis","volume":"68","author":"Voges","year":"1999","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nsb0395-199","article-title":"Conformational constraints in protein degradation by the 20S proteasome","volume":"2","author":"Wenzel","year":"1995","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.gendis.2023.06.037_bib50","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1146\/annurev-physiol-021317-121303","article-title":"Mechanical protein unfolding and degradation","volume":"80","author":"Olivares","year":"2018","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib51","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S1097-2765(01)00407-5","article-title":"Proteins are unfolded on the surface of the ATPase ring before transport into the proteasome","volume":"8","author":"Navon","year":"2001","journal-title":"Mol Cell"},{"issue":"6808","key":"10.1016\/j.gendis.2023.06.037_bib52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/35040607","article-title":"Structural basis for the activation of 20S proteasomes by 11S regulators","volume":"408","author":"Whitby","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1097-2765(02)00775-X","article-title":"ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation","volume":"11","author":"Benaroudj","year":"2003","journal-title":"Mol Cell"},{"issue":"31","key":"10.1016\/j.gendis.2023.06.037_bib54","doi-asserted-by":"crossref","first-page":"22369","DOI":"10.1016\/S0021-9258(18)41681-X","article-title":"Purification of an 11 S regulator of the multicatalytic protease","volume":"267","author":"Dubiel","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gendis.2023.06.037_bib55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fmicb.2015.00021","article-title":"The immunoproteasome and viral infection: a complex regulator of inflammation","volume":"6","author":"McCarthy","year":"2015","journal-title":"Front Microbiol"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib56","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.7150\/thno.48744","article-title":"Proteasome activator PA200 maintains stability of histone marks during transcription and aging","volume":"11","author":"Jiang","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.gendis.2023.06.037_bib57","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.genet.30.1.405","article-title":"Ubiquitin-dependent protein degradation","volume":"30","author":"Hochstrasser","year":"1996","journal-title":"Annu Rev Genet"},{"issue":"5","key":"10.1016\/j.gendis.2023.06.037_bib58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1535-6108(04)00120-5","article-title":"The development of proteasome inhibitors as anticancer drugs","volume":"5","author":"Adams","year":"2004","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.gendis.2023.06.037_bib59","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.gendis.2023.06.037_bib60","first-page":"4996","article-title":"Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model","volume":"62","author":"LeBlanc","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2023.06.037_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.100663","article-title":"Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance","volume":"48","author":"Narayanan","year":"2020","journal-title":"Drug Resist Updates"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib62","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri.2017.52","article-title":"The non-canonical NF-\u03baB pathway in immunity and inflammation","volume":"17","author":"Sun","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib63","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct Targeted Ther"},{"issue":"13","key":"10.1016\/j.gendis.2023.06.037_bib64","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1101\/gad.9.13.1586","article-title":"Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway","volume":"9","author":"Chen","year":"1995","journal-title":"Genes Dev"},{"issue":"24","key":"10.1016\/j.gendis.2023.06.037_bib65","doi-asserted-by":"crossref","first-page":"11259","DOI":"10.1073\/pnas.92.24.11259","article-title":"Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination","volume":"92","author":"Scherer","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib66","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1101\/gad.13.3.284","article-title":"Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb\/beta-TrCP","volume":"13","author":"Spencer","year":"1999","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib67","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1101\/gad.13.3.270","article-title":"The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro","volume":"13","author":"Winston","year":"1999","journal-title":"Genes Dev"},{"issue":"22","key":"10.1016\/j.gendis.2023.06.037_bib68","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2023.06.037_bib69","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12015-016-9691-3","article-title":"Eliminating cancer stem cells by targeting embryonic signaling pathways","volume":"13","author":"Oren","year":"2017","journal-title":"Stem Cell Rev Rep"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib71","doi-asserted-by":"crossref","first-page":"R62","DOI":"10.1016\/j.cub.2006.01.004","article-title":"Wnt signaling: a shaggy dogma tale","volume":"16","author":"Heeg-Truesdell","year":"2006","journal-title":"Curr Biol"},{"issue":"13","key":"10.1016\/j.gendis.2023.06.037_bib72","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/emboj\/16.13.3797","article-title":"Beta-catenin is a target for the ubiquitin-proteasome pathway","volume":"16","author":"Aberle","year":"1997","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","article-title":"Wnt\/beta-catenin pathway: modulating anticancer immune response","volume":"10","author":"Pai","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.gendis.2023.06.037_bib74","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.tibs.2018.06.003","article-title":"Is \u03b2-catenin a druggable target for cancer therapy?","volume":"43","author":"Cui","year":"2018","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.gendis.2023.06.037_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104794","article-title":"Targeting the \u03b2-catenin signaling for cancer therapy","volume":"160","author":"Zhang","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.gendis.2023.06.037_bib76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2017.11.002","article-title":"Targeting the Wnt\/beta-catenin pathway in cancer: update on effectors and inhibitors","volume":"62","author":"Krishnamurthy","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.gendis.2023.06.037_bib77","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3389\/fphar.2020.00457","article-title":"Terphenyllin suppresses orthotopic pancreatic tumor growth and prevents metastasis in mice","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib78","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/jcmm.13346","article-title":"The natural agent Rhein induces \u03b2-catenin degradation and tumour growth arrest","volume":"22","author":"Liu","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib79","first-page":"3599","article-title":"Baicalin inhibits the metastasis of highly aggressive breast cancer cells by reversing epithelial-to-mesenchymal transition by targeting \u03b2-catenin signaling","volume":"38","author":"Zhou","year":"2017","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib80","doi-asserted-by":"crossref","first-page":"E572","DOI":"10.3390\/nu9060572","article-title":"(-)-epigallocatechin-3-gallate inhibits colorectal cancer stem cells by suppressing Wnt\/\u03b2-catenin pathway","volume":"9","author":"Chen","year":"2017","journal-title":"Nutrients"},{"issue":"6810","key":"10.1016\/j.gendis.2023.06.037_bib81","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"56","key":"10.1016\/j.gendis.2023.06.037_bib82","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","article-title":"Control of apoptosis by p53","volume":"22","author":"Fridman","year":"2003","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib83","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF01535205","article-title":"Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line","volume":"13","author":"Cahilly-Snyder","year":"1987","journal-title":"Somat Cell Mol Genet"},{"issue":"7","key":"10.1016\/j.gendis.2023.06.037_bib84","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","article-title":"The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation","volume":"69","author":"Momand","year":"1992","journal-title":"Cell"},{"issue":"6423","key":"10.1016\/j.gendis.2023.06.037_bib85","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/362857a0","article-title":"Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53","volume":"362","author":"Oliner","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib86","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1573406413666171020115539","article-title":"USP7: target validation and drug discovery for cancer therapy","volume":"14","author":"Zhou","year":"2018","journal-title":"Med Chem"},{"issue":"6630","key":"10.1016\/j.gendis.2023.06.037_bib87","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib88","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-5793(97)01480-4","article-title":"Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53","volume":"420","author":"Honda","year":"1997","journal-title":"FEBS Lett"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib89","doi-asserted-by":"crossref","first-page":"a026336","DOI":"10.1101\/cshperspect.a026336","article-title":"The role of MDM2 amplification and overexpression in tumorigenesis","volume":"6","author":"Oliner","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib90","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"33","key":"10.1016\/j.gendis.2023.06.037_bib91","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202204395","article-title":"Discovery of a potent and selective degrader for USP7","volume":"61","author":"Pei","year":"2022","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.gendis.2023.06.037_bib92","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fcell.2020.00233","article-title":"Targeting USP7-mediated deubiquitination of MDM2\/MDMX-p53 pathway for cancer therapy: are we there yet?","volume":"8","author":"Qi","year":"2020","journal-title":"Front Cell Dev Biol"},{"issue":"11","key":"10.1016\/j.gendis.2023.06.037_bib93","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nrc1209","article-title":"AP-1: a double-edged sword in tumorigenesis","volume":"3","author":"Eferl","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.gendis.2023.06.037_bib94","doi-asserted-by":"crossref","first-page":"E131","DOI":"10.1038\/ncb0502-e131","article-title":"AP-1 as a regulator of cell life and death","volume":"4","author":"Shaulian","year":"2002","journal-title":"Nat Cell Biol"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib95","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10495-006-4689-y","article-title":"JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL\/caspase-8 and mitochondria-dependent pathways","volume":"11","author":"Lauricella","year":"2006","journal-title":"Apoptosis"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib96","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/CIRCULATIONAHA.118.034588","article-title":"Uremic toxin indoxyl sulfate promotes proinflammatory macrophage activation via the interplay of OATP2B1 and Dll4-Notch signaling","volume":"139","author":"Nakano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.gendis.2023.06.037_bib97","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.semcdb.2018.10.009","article-title":"Proteostasis in the Hedgehog signaling pathway","volume":"93","author":"Liu","year":"2019","journal-title":"Semin Cell Dev Biol"},{"issue":"12","key":"10.1016\/j.gendis.2023.06.037_bib98","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1158\/2159-8290.CD-20-0815","article-title":"AKT degradation selectively inhibits the growth of PI3K\/PTEN pathway-mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B","volume":"11","author":"Xu","year":"2021","journal-title":"Cancer Discov"},{"issue":"11","key":"10.1016\/j.gendis.2023.06.037_bib99","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1093\/emboj\/18.11.3054","article-title":"Excess beta-catenin promotes accumulation of transcriptionally active p53","volume":"18","author":"Damalas","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.gendis.2023.06.037_bib100","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1749-6632.2002.tb04669.x","article-title":"Regulation of p53: intricate loops and delicate balances","volume":"973","author":"Oren","year":"2002","journal-title":"Ann N Y Acad Sci"},{"issue":"20","key":"10.1016\/j.gendis.2023.06.037_bib101","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1128\/MCB.21.20.6768-6781.2001","article-title":"Down-regulation of beta-catenin by activated p53","volume":"21","author":"Sadot","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"25","key":"10.1016\/j.gendis.2023.06.037_bib102","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1038\/sj.onc.1207587","article-title":"Downregulation of \u03b2-catenin by p53 involves changes in the rate of \u03b2-catenin phosphorylation and Axin dynamics","volume":"23","author":"Levina","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib103","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tibs.2005.04.005","article-title":"Regulated protein degradation","volume":"30","author":"Varshavsky","year":"2005","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib104","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2011.03.007","article-title":"Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting","volume":"1824","author":"Ciechanover","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.gendis.2023.06.037_bib105","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","article-title":"The ubiquitin system","volume":"67","author":"Hershko","year":"1998","journal-title":"Annu Rev Biochem"},{"issue":"5293","key":"10.1016\/j.gendis.2023.06.037_bib106","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1126\/science.274.5293.1652","article-title":"How proteolysis drives the cell cycle","volume":"274","author":"King","year":"1996","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib107","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cell.2015.08.063","article-title":"CDK7-dependent transcriptional addiction in triple-negative breast cancer","volume":"163","author":"Wang","year":"2015","journal-title":"Cell"},{"issue":"7672","key":"10.1016\/j.gendis.2023.06.037_bib108","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature23880","article-title":"Competing memories of mitogen and p53 signalling control cell-cycle entry","volume":"549","author":"Yang","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib109","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cellsig.2005.02.005","article-title":"Role of CDK\/cyclin complexes in transcription and RNA splicing","volume":"17","author":"Loyer","year":"2005","journal-title":"Cell Signal"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib110","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.V95.2.619","article-title":"Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma","volume":"95","author":"Chiarle","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib111","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0002-9440(10)65277-7","article-title":"p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers","volume":"154","author":"Lloyd","year":"1999","journal-title":"Am J Pathol"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib112","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21414","article-title":"Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies","volume":"104","author":"Ludwig","year":"2005","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.gendis.2023.06.037_bib113","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1158\/0008-5472.CAN-08-0257","article-title":"Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells","volume":"68","author":"Chen","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2023.06.037_bib114","article-title":"PS341 inhibits hepatocellular and colorectal cancer cells through the FOXO3\/CTNNB1 signaling pathway","volume":"6","author":"Yang","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib115","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s00535-012-0675-z","article-title":"Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis","volume":"48","author":"Saeki","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gendis.2023.06.037_bib116","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.biochi.2015.02.015","article-title":"Impairment of the Pin1\/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells","volume":"112","author":"Farra","year":"2015","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib117","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.biochi.2008.10.015","article-title":"Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels","volume":"91","author":"Baiz","year":"2009","journal-title":"Biochimie"},{"key":"10.1016\/j.gendis.2023.06.037_bib118","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3389\/fonc.2019.01283","article-title":"PA28\u03b1\/\u03b2 promote breast cancer cell invasion and metastasis via down-regulation of CDK15","volume":"9","author":"Li","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib119","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.jbchem.a124327","article-title":"Interferon-gamma induces different subunit organizations and functional diversity of proteasomes","volume":"115","author":"Aki","year":"1994","journal-title":"J Biochem"},{"issue":"12","key":"10.1016\/j.gendis.2023.06.037_bib120","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1016\/j.bmc.2013.01.056","article-title":"Intracellular protein degradation: from a vague idea through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting","volume":"21","author":"Ciechanover","year":"2013","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib121","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/35056572","article-title":"Antigen processing by the proteasome","volume":"2","author":"Kloetzel","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib122","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri2687","article-title":"Proteasomes in immune cells: more than peptide producers?","volume":"10","author":"Groettrup","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"10.1016\/j.gendis.2023.06.037_bib123","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00018-012-0938-0","article-title":"Emerging roles of immunoproteasomes beyond MHC class I antigen processing","volume":"69","author":"Ebstein","year":"2012","journal-title":"Cell Mol Life Sci"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib124","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0167-5699(00)01692-3","article-title":"Antigen-processing machinery breakdown and tumor growth","volume":"21","author":"Seliger","year":"2000","journal-title":"Immunol Today"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib125","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00008390-200308000-00006","article-title":"Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression","volume":"13","author":"Dissemond","year":"2003","journal-title":"Melanoma Res"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib126","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.4049\/jimmunol.167.9.5420","article-title":"Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6","volume":"167","author":"Evans","year":"2001","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.gendis.2023.06.037_bib127","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1158\/0008-5472.CAN-10-1883","article-title":"The LMP7-K allele of the immunoproteasome exhibits reduced transcript stability and predicts high risk of colon cancer","volume":"71","author":"Fellerhoff","year":"2011","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib128","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/0008-5472.CAN-05-2872","article-title":"Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency","volume":"66","author":"Heink","year":"2006","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.gendis.2023.06.037_bib129","first-page":"3660","article-title":"Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines","volume":"58","author":"Johnsen","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2023.06.037_bib130","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/541984","article-title":"New insights into the function of the immunoproteasome in immune and nonimmune cells","volume":"2015","author":"Kimura","year":"2015","journal-title":"J Immunol Res"},{"issue":"19","key":"10.1016\/j.gendis.2023.06.037_bib131","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2008-07-171637","article-title":"Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors","volume":"113","author":"Kuhn","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib132","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/j.seminhematol.2012.04.003","article-title":"The immunoproteasome as a target in hematologic malignancies","volume":"49","author":"Kuhn","year":"2012","journal-title":"Semin Hematol"},{"issue":"31","key":"10.1016\/j.gendis.2023.06.037_bib133","doi-asserted-by":"crossref","first-page":"50873","DOI":"10.18632\/oncotarget.15141","article-title":"Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice","volume":"8","author":"Koerner","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.gendis.2023.06.037_bib134","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007857","article-title":"Immunoproteasome overexpression underlies the pathogenesis of thyroid oncocytes and primary hypothyroidism: studies in humans and mice","volume":"4","author":"Kimura","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib135","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2141.2010.08491.x","article-title":"PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo","volume":"152","author":"Singh","year":"2011","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.gendis.2023.06.037_bib136","doi-asserted-by":"crossref","first-page":"E1555","DOI":"10.1073\/pnas.1521812113","article-title":"Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome","volume":"113","author":"Tripathi","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1016\/j.gendis.2023.06.037_bib137","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1182\/blood-2008-11-187633","article-title":"Exclusive expression of proteasome subunit{beta}5t in the human thymic cortex","volume":"113","author":"Tomaru","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.gendis.2023.06.037_bib138","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/eji.201041375","article-title":"Ontogeny of thymic cortical epithelial cells expressing the thymoproteasome subunit \u03b25t","volume":"41","author":"Ripen","year":"2011","journal-title":"Eur J Immunol"},{"issue":"24","key":"10.1016\/j.gendis.2023.06.037_bib139","doi-asserted-by":"crossref","first-page":"9885","DOI":"10.1073\/pnas.1301799110","article-title":"Aire-expressing thymic medullary epithelial cells originate from \u03b25t-expressing progenitor cells","volume":"110","author":"Ohigashi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.gendis.2023.06.037_bib140","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.chembiol.2010.05.027","article-title":"Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit \u03b25t","volume":"17","author":"Florea","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/j.gendis.2023.06.037_bib141","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1038\/ncomms8484","article-title":"Thymoproteasomes produce unique peptide motifs for positive selection of CD8+ T cells","volume":"6","author":"Sasaki","year":"2015","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib142","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00251-011-0558-0","article-title":"Comparative genomic analysis of the proteasome \u03b25t subunit gene: implications for the origin and evolution of thymoproteasomes","volume":"64","author":"Sutoh","year":"2012","journal-title":"Immunogenetics"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib143","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2009.10.009","article-title":"Thymoproteasome shapes immunocompetent repertoire of CD8+ T cells","volume":"32","author":"Nitta","year":"2010","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib144","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.coi.2008.03.002","article-title":"Thymoproteasome: probable role in generating positively selecting peptides","volume":"20","author":"Murata","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"10.1016\/j.gendis.2023.06.037_bib145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.smim.2010.04.012","article-title":"Role of thymic cortex-specific self-peptides in positive selection of T cells","volume":"22","author":"Takahama","year":"2010","journal-title":"Semin Immunol"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib146","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nri3667","article-title":"Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)","volume":"14","author":"Klein","year":"2014","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.gendis.2023.06.037_bib147","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/ni.3480","article-title":"Specialized proteasome subunits have an essential role in the thymic selection of CD8+ T cells","volume":"17","author":"Kincaid","year":"2016","journal-title":"Nat Immunol"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib148","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41590-018-0186-z","article-title":"The immunoproteasome and thymoproteasome: functions, evolution and human disease","volume":"19","author":"Murata","year":"2018","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib149","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00251-018-1081-3","article-title":"Thymoproteasome and peptidic self","volume":"71","author":"Takahama","year":"2019","journal-title":"Immunogenetics"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib150","first-page":"3","article-title":"The peptidic self model: a hypothesis on the molecular nature of the immunological self","volume":"137D","author":"Kourilsky","year":"1986","journal-title":"Ann Inst Pasteur Immunol"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib151","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.celrep.2018.12.078","article-title":"Restricted expression of the thymoproteasome is required for thymic selection and peripheral homeostasis of CD8+ T cells","volume":"26","author":"Tomaru","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.gendis.2023.06.037_bib152","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.immunol.21.120601.141107","article-title":"Positive and negative selection of T cells","volume":"21","author":"Starr","year":"2003","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib153","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.it.2008.03.003","article-title":"Modest cortex and promiscuous medulla for thymic repertoire formation","volume":"29","author":"Takahama","year":"2008","journal-title":"Trends Immunol"},{"issue":"10","key":"10.1016\/j.gendis.2023.06.037_bib154","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 world health organization classification of tumors of the thymus: Continuity and changes","volume":"10","author":"Marx","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib155","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1097\/PAS.0b013e3182237f5d","article-title":"Expression of proteasome subunit \u03b25t in thymic epithelial tumors","volume":"35","author":"Yamada","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib156","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/jclinpath-2013-201930","article-title":"Expression of thymoproteasome subunit \u03b25t in type AB thymoma","volume":"67","author":"Yamada","year":"2014","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.gendis.2023.06.037_bib157","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0065-2571(93)90016-7","article-title":"Regulation of proteasome expression in developing and transformed cells","volume":"33","author":"Ichihara","year":"1993","journal-title":"Adv Enzym Regul"},{"issue":"18","key":"10.1016\/j.gendis.2023.06.037_bib158","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.gendis.2023.06.037_bib159","first-page":"6677","article-title":"Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells","volume":"51","author":"Kanayama","year":"1991","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib160","first-page":"687","article-title":"Proteasome-mediated degradation of BRCA1 protein in MCF-7 human breast cancer cells","volume":"19","author":"Choi","year":"2001","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib161","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-006-9393-7","article-title":"Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics","volume":"104","author":"Deng","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"10.1016\/j.gendis.2023.06.037_bib162","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1128\/jvi.70.8.5582-5591.1996","article-title":"Proteasome complex as a potential cellular target of hepatitis B virus X protein","volume":"70","author":"Huang","year":"1996","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib163","doi-asserted-by":"crossref","first-page":"7231","DOI":"10.1128\/JVI.73.9.7231-7240.1999","article-title":"Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex","volume":"73","author":"Hu","year":"1999","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib164","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1128\/JVI.78.9.4566-4572.2004","article-title":"Inhibition of cellular proteasome activities enhances hepadnavirus replication in an HBX-dependent manner","volume":"78","author":"Zhang","year":"2004","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib165","first-page":"441","article-title":"The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer","volume":"19","author":"Hu","year":"2008","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib166","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cell.2011.02.005","article-title":"ATP binds to proteasomal ATPases in pairs with distinct functional effects, implying an ordered reaction cycle","volume":"144","author":"Smith","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.gendis.2023.06.037_bib167","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.cell.2009.05.008","article-title":"Assembly pathway of the mammalian proteasome base sub complex is mediated by multiple specific chaperones","volume":"137","author":"Kaneko","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.gendis.2023.06.037_bib168","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.canlet.2018.05.018","article-title":"PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation","volume":"430","author":"Li","year":"2018","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib169","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.bjc.6605478","article-title":"PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer","volume":"102","author":"Munk\u00e1csy","year":"2010","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib170","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.3390\/ph10020040","article-title":"Novel proteasome inhibitors and histone deacetylase inhibitors: progress in myeloma therapeutics","volume":"10","author":"Chhabra","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib171","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/sj.cdd.4400505","article-title":"The role of the ubiquitin-proteasome pathway in apoptosis","volume":"6","author":"Orlowski","year":"1999","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib172","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib173","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/jjco\/hyy108","article-title":"Proteasome inhibitors for multiple myeloma","volume":"48","author":"Okazuka","year":"2018","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib174","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2174\/156800911794519752","article-title":"Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives","volume":"11","author":"Chen","year":"2011","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clml.2018.08.016","article-title":"Role of proteasome inhibitors in relapsed and\/or refractory multiple myeloma","volume":"19","author":"Leleu","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"7","key":"10.1016\/j.gendis.2023.06.037_bib176","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1158\/0008-5472.CAN-05-2961","article-title":"Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells","volume":"66","author":"Nawrocki","year":"2006","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.gendis.2023.06.037_bib177","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2013-01-481325","article-title":"Panorama 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma","volume":"122","author":"Richardson","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.gendis.2023.06.037_bib178","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S1471-4914(02)02315-8","article-title":"Proteasome inhibition: a novel approach to cancer therapy","volume":"8","author":"Adams","year":"2002","journal-title":"Trends Mol Med"},{"issue":"12","key":"10.1016\/j.gendis.2023.06.037_bib179","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/sj.cdd.4400436","article-title":"Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts","volume":"5","author":"An","year":"1998","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib180","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jcb.1150","article-title":"26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer","volume":"82","author":"Shah","year":"2001","journal-title":"J Cell Biochem"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib181","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1349-7006.2004.tb03200.x","article-title":"Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK\/c-Jun\/AP-1 signaling","volume":"95","author":"Yang","year":"2004","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib182","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-14-0005","article-title":"The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors","volume":"22","author":"Johnson","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.gendis.2023.06.037_bib183","first-page":"900","article-title":"Research progress in proteasome inhibitor resistance to multiple myeloma","volume":"46","author":"Wu","year":"2021","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib184","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J Cell Mol Med"},{"issue":"11","key":"10.1016\/j.gendis.2023.06.037_bib185","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","article-title":"Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis","volume":"59","author":"Shah","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib186","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.gendis.2023.06.037_bib187","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/neuonc\/noab001","article-title":"PTEN deficiency leads to proteasome addiction: a novel vulnerability in glioblastoma","volume":"23","author":"Benitez","year":"2021","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib188","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","article-title":"Cardiovascular complications of proteasome inhibitors used in multiple myeloma","volume":"26","author":"Cole","year":"2018","journal-title":"Cardiol Rev"},{"issue":"12","key":"10.1016\/j.gendis.2023.06.037_bib189","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/14789450.2018.1543595","article-title":"The power of proteasome inhibition in multiple myeloma","volume":"15","author":"Guerrero-Garcia","year":"2018","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.gendis.2023.06.037_bib190","article-title":"Novel proteasome inhibitor ixazomib sensitizes neuroblastoma cells to doxorubicin treatment","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"issue":"26","key":"10.1016\/j.gendis.2023.06.037_bib191","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.gendis.2023.06.037_bib192","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib193","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.gendis.2023.06.037_bib194","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib195","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13046-022-02436-9","article-title":"Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors","volume":"41","author":"Lim","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib196","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor velcade (bortezomib)","volume":"22","author":"Adams","year":"2004","journal-title":"Cancer Invest"},{"issue":"5\u20136","key":"10.1016\/j.gendis.2023.06.037_bib197","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov Today"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib198","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.gendis.2023.06.037_bib199","doi-asserted-by":"crossref","DOI":"10.1038\/srep18953","article-title":"Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo","volume":"6","author":"Manton","year":"2016","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.gendis.2023.06.037_bib200","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro Oncol"},{"issue":"12","key":"10.1016\/j.gendis.2023.06.037_bib201","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.7150\/thno.42705","article-title":"Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition","volume":"10","author":"Raninga","year":"2020","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib202","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1021\/jm801329v","article-title":"Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047)","volume":"52","author":"Zhou","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.gendis.2023.06.037_bib203","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1158\/1078-0432.CCR-12-1213","article-title":"Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy","volume":"18","author":"Zang","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.gendis.2023.06.037_bib204","doi-asserted-by":"crossref","first-page":"34988","DOI":"10.18632\/oncotarget.9222","article-title":"Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma","volume":"7","author":"Vandewynckel","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.gendis.2023.06.037_bib205","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib206","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.kint.2017.09.023","article-title":"Immunoproteasome inhibition prevents chronic antibody-mediated allograft rejection in renal transplantation","volume":"93","author":"Li","year":"2018","journal-title":"Kidney Int"},{"issue":"31","key":"10.1016\/j.gendis.2023.06.037_bib207","doi-asserted-by":"crossref","first-page":"50447","DOI":"10.18632\/oncotarget.14579","article-title":"Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7","volume":"8","author":"Vachharajani","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.gendis.2023.06.037_bib208","doi-asserted-by":"crossref","first-page":"200","DOI":"10.15252\/emmm.201708089","article-title":"The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis","volume":"10","author":"Althof","year":"2018","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib209","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4049\/jimmunol.0903182","article-title":"Prevention of experimental colitis by a selective inhibitor of the immunoproteasome","volume":"185","author":"Basler","year":"2010","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib210","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/bph.14069","article-title":"Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome","volume":"175","author":"Basler","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib211","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90451-9","article-title":"Activity of immunoproteasome inhibitor ONX-0914 in acute lymphoblastic leukemia expressing MLL-AF4 fusion protein","volume":"11","author":"Jenkins","year":"2021","journal-title":"Sci Rep"},{"issue":"22","key":"10.1016\/j.gendis.2023.06.037_bib212","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.3390\/cancers14225712","article-title":"ONX-0914 induces apoptosis and autophagy with p53 regulation in human glioblastoma cells","volume":"14","author":"Chang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"52","key":"10.1016\/j.gendis.2023.06.037_bib213","doi-asserted-by":"crossref","first-page":"E8425","DOI":"10.1073\/pnas.1618548114","article-title":"Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice","volume":"113","author":"Sula Karreci","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O","article-title":"Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators","volume":"187","author":"Yew","year":"2001","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.gendis.2023.06.037_bib215","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1158\/1535-7163.MCT-10-0794","article-title":"Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A","volume":"10","author":"Chen","year":"2011","journal-title":"Mol Cancer Therapeut"},{"issue":"12","key":"10.1016\/j.gendis.2023.06.037_bib216","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052576","article-title":"HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib217","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jhep.2009.10.011","article-title":"Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation","volume":"52","author":"Chen","year":"2010","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.gendis.2023.06.037_bib218","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00535-013-0796-z","article-title":"Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases","volume":"49","author":"Honma","year":"2014","journal-title":"J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib219","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3892\/mmr.2014.2736","article-title":"Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells","volume":"11","author":"Hou","year":"2015","journal-title":"Mol Med Rep"},{"issue":"19","key":"10.1016\/j.gendis.2023.06.037_bib220","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1158\/1078-0432.CCR-14-2067","article-title":"Hepatitis B virus X protein (HBx) is responsible for resistance to targeted therapies in hepatocellular carcinoma: Ex vivo culture evidence","volume":"21","author":"Huang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.gendis.2023.06.037_bib221","doi-asserted-by":"crossref","first-page":"5560","DOI":"10.1002\/cncr.27586","article-title":"Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma","volume":"118","author":"Hui","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.gendis.2023.06.037_bib222","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-2407-12-166","article-title":"Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model","volume":"12","author":"Wang","year":"2012","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib223","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2009","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib224","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib225","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.gendis.2023.06.037_bib226","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gut.2009.196519","article-title":"Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma","volume":"59","author":"Boozari","year":"2010","journal-title":"Gut"},{"issue":"5\u20136","key":"10.1016\/j.gendis.2023.06.037_bib227","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.lfs.2009.12.003","article-title":"Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B","volume":"86","author":"Ko","year":"2010","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.gendis.2023.06.037_bib228","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-016-0307-9","article-title":"Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma","volume":"9","author":"Jayachandran","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.gendis.2023.06.037_bib229","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4252\/wjsc.v9.i9.159","article-title":"Murine hepatocellular carcinoma derived stem cells reveal epithelial-to-mesenchymal plasticity","volume":"9","author":"Jayachandran","year":"2017","journal-title":"World J Stem Cell"},{"issue":"13","key":"10.1016\/j.gendis.2023.06.037_bib230","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1158\/1078-0432.CCR-14-1936","article-title":"Keratin 19, a cancer stem cell marker in human hepatocellular carcinoma","volume":"21","author":"Kawai","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304223003525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304223003525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T02:01:54Z","timestamp":1715047314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304223003525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":230,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2352304223003525"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2023.06.037","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of proteasomes in tumorigenesis","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2023.06.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101070"}}